|46.11||-0.0900||-0.19%||Vol 196.56K||1Y Perf 147.18%|
|Apr 16th, 2021 10:48 DELAYED|
|- -%||- -|
|Target Price||41.73||Analyst Rating||Moderate Buy 1.71|
|Potential %||-9.18||Finscreener Ranking||+ 39.62|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★+ 43.80|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★ 59.06|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||6.61B||Earnings Rating||Strong Sell|
|Price Range Ratio 52W %||72.79||Earnings Date||10th May 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||10th May 2021|
|Estimated EPS Next Report||0.31|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||880.74K|
|Avg. Monthly Volume||1.17M|
|Avg. Quarterly Volume||1.39M|
Halozyme Therapeutics Inc. (NASDAQ: HALO) stock closed at 46.2 per share at the end of the most recent trading day (a 0.54% change compared to the prior day closing price) with a volume of 887.91K shares and market capitalization of 6.61B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 136 people. Halozyme Therapeutics Inc. CEO is Helen I. Torley.
The one-year performance of Halozyme Therapeutics Inc. stock is 147.18%, while year-to-date (YTD) performance is 8.17%. HALO stock has a five-year performance of 285.96%. Its 52-week range is between 18.58 and 56.4, which gives HALO stock a 52-week price range ratio of 72.79%
Halozyme Therapeutics Inc. currently has a PE ratio of 46.40, a price-to-book (PB) ratio of 40.04, a price-to-sale (PS) ratio of 25.41, a price to cashflow ratio of 107.70, a PEG ratio of 2.32, a ROA of 21.59%, a ROC of 10.85% and a ROE of 102.88%. The company’s profit margin is 56.72%, its EBITDA margin is 57.20%, and its revenue ttm is $242.24 Million , which makes it $1.69 revenue per share.
Of the last four earnings reports from Halozyme Therapeutics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $0.31 for the next earnings report. Halozyme Therapeutics Inc.’s next earnings report date is 10th May 2021.
The consensus rating of Wall Street analysts for Halozyme Therapeutics Inc. is Moderate Buy (1.71), with a target price of $41.73, which is -9.18% compared to the current price. The earnings rating for Halozyme Therapeutics Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Halozyme Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Halozyme Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 11.79, ATR14 : 2.58, CCI20 : 225.47, Chaikin Money Flow : 0.01, MACD : -0.92, Money Flow Index : 83.57, ROC : 14.22, RSI : 50.39, STOCH (14,3) : 86.59, STOCH RSI : 1.00, UO : 56.86, Williams %R : -13.41), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Halozyme Therapeutics Inc. in the last 12-months were: Connie L. Matsui (Sold 32 000 shares of value $865 792 ), Elaine D. Sun (Option Excercise at a value of $0), Helen I. Torley (Option Excercise at a value of $0), Helen I. Torley (Sold 200 000 shares of value $8 865 189 ), James M. Daly (Sold 79 037 shares of value $2 418 587 ), Jeffrey W. Henderson (Sold 24 498 shares of value $981 757 ), Kenneth J. Kelley (Sold 101 549 shares of value $4 237 715 ), Masaru Matsuda (Option Excercise at a value of $0), Michael LaBarre (Option Excercise at a value of $609 499), Michael LaBarre (Sold 140 400 shares of value $4 921 238 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.